Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q92974

UPID:
ARHG2_HUMAN

ALTERNATIVE NAMES:
Guanine nucleotide exchange factor H1; Microtubule-regulated Rho-GEF; Proliferating cell nucleolar antigen p40

ALTERNATIVE UPACC:
Q92974; D3DVA6; O75142; Q15079; Q5VY92; Q8TDA3; Q8WUG4; Q9H023

BACKGROUND:
The protein Rho guanine nucleotide exchange factor 2, also known as Guanine nucleotide exchange factor H1, plays a critical role in activating Rho-GTPases, thereby regulating epithelial barrier permeability, antigen presentation, and cancer. It forms an intracellular sensing system for microbial effectors, essential for innate immune response and NF-kappaB signaling pathways activation.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in a neurodevelopmental disorder characterized by intellectual disability and midbrain-hindbrain malformations, RhoGEF2 represents a promising target for therapeutic intervention. Exploring RhoGEF2's functions and mechanisms could lead to novel treatments for this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.